Paul Duffy Presents at EUROTOX 2018

Dr Paul Duffy will be speaking at EUROTOX this September. On Monday 3rd of September at 16:30 in the SILVER Hall Paul will address “Old drugs in new guises: the toxicology of repurposing” chaired and introduced by Ruth Roberts and Dr Miranda Cornet from UCB in Belgium.  Paul will present case studies to illustrate the necessary consideration of the non-clinical toxicology profile when repurposing drugs, including the work done at ApconiX in collaboration with Compass on repurposing psychoactives in psychiatry.  As Paul commented; “Some very good ideas for redeveloping existing therapies in new indications can only succeed the toxicity profiles are compatible with the new indication”.

Ruth will also be co-chairing Session 2 on “Ensuring validity of in vitro replacements: what is needed for regulatory decision making?” with Professor Heather Wallace, University of Aberdeen on Monday morning at 10:00 in the COPPER Hall.

EUROTOX is being held in Brussels this year and runs the 2nd to 5th of September 2018.  For more information see the EUROTOX website.  See the full programme here.

By |2018-08-23T12:05:58+00:00August 22nd, 2018|Toxicology, Events|Comments Off on Paul Duffy Presents at EUROTOX 2018

About the Author:

Dr Richard Knight PhD, ERT, is a Director and Co-founder of ApconiX, a preclinical toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts. Richard graduated from the University of Bradford in 1989 with a degree in Biomedical Sciences (Pharmacology) before gaining a PhD at the University of Leeds researching the role of adenosine receptors in renal function and toxicity. His research then included post-doctoral studies at University of California, Los Angeles (UCLA) into the effects of ischaemia/reperfusion injury on cardiac metabolism. Richard joined Zeneca Pharmaceuticals, Safety of Medicines Group in 1996 as a Study Director, and then Project Toxicologist across multiple therapy areas, from early discovery through to market. As Lead Toxicologist for Oncology, Richard was a member of both the Drug Safety and Metabolism, and Oncology Leadership teams with responsibility for safety across the AZ oncology portfolio. In this senior role he provided leadership and mentoring support to other project toxicologists. Richard has worked on many drug platforms over this time including small molecules, biologics, proteins and oligonucleotides and has been involved in bringing over 30 new candidate drugs into clinical trials and 5 to marketing approval.